|
Post by JHam on Feb 4, 2021 16:02:45 GMT
Crazy battle going on right now trying to keep it above $7. Likely to be some wild swings over the next few days. Longs won the first round Over 2 million shares traded and it's still early. Let's get $8 today. Look out, KMPH now trending on ST.
|
|
|
Post by JHam on Feb 4, 2021 16:18:38 GMT
One other thing, now that we know the charts are all messed up I can confirm that this stock never made it to $20 in Dec. The all time high is $7.75 (adjusted for post r/s), and were just about to cross it.
|
|
|
Post by jamesjohnson12 on Feb 4, 2021 17:00:06 GMT
Good call on this one JHAM. I missed CPSH too, but between this, INMB, and ATHX I am having a pretty good week!! This one looks like it could be a runner. Thanks for bringing it to our attention.
|
|
|
Post by selluwud on Feb 4, 2021 18:34:21 GMT
Good call on this one JHAM. I missed CPSH too, but between this, INMB, and ATHX I am having a pretty good week!! This one looks like it could be a runner. Thanks for bringing it to our attention. Same here. Other than Parkervision which until today has more than tripled for me. Spooky week in advancing the worth of my portfolio. Now that it has been spoken out loud, there's not a enough wood to knock on. LOL
|
|
|
Post by JHam on Feb 5, 2021 1:12:36 GMT
Today’s action didn’t really surprise me. It’s getting pumped so hard that it was inevitable that many would want to do a quick flip off of the highs. Long way to go until March. I’d love to see this more than double prior, a la INMB.
|
|
|
Post by JHam on Feb 5, 2021 17:56:11 GMT
New article just published: www.bizjournals.com/orlando/news/2021/02/05/psych-drug-maker-kempharm-to-add-jobs-if-fda-oks-n.html
By Alex Soderstrom – Staff Writer, Orlando Business Journal 45 minutes ago Drug maker KemPharm Inc. is on the verge of a company breakthrough. The Food and Drug Administration in March may approve the Celebration-based company’s attention deficit hyperactivity disorder drug KP415. The treatment stands out from other ADHD treatments on the market because of how quickly it kicks in and how long it lasts, and it may be a financial boost for the pre-revenue company.
KemPharm (Nasdaq: KMPH) is partnered with Menlo Park, California-based Corium Inc., which will commercialize the drug once approved. That, and other ongoing drug developments, will necessitate future hiring to KemPharm’s staff of 23 workers, co-founder and CEO Travis Mickle told Orlando Business Journal.
The growth of innovative companies like KemPharm is important because it can create high-wage jobs. Those companies also create innovative solutions for businesses and consumers, help develop a community and make it easier for other new companies to form in the future.
The pharmaceutical and life sciences industry is projected to experience growth in the number of merger and acquisition deals in 2021, according to a report from London-based accounting giant PricewaterhouseCoopers. The industry is expected to generate between $250 billion-$275 billion in deals, up from $184 billion in 2020. The industry’s need for scale and innovation will fuel this growth, Sky Milch, PWC’s U.S. deal leader for the pharmaceuticals and life sciences, said in the report. “Larger transformational pharma and medical device deals, combined with a flurry of biotech deals, will be the driver.”
Here, Mickle shares more about how the approval of KP415 would transform the company, how the new drug differs from others and more.
How does KP415 differ from other ADHD treatments on the market? We designed it to be similar to the product that I developed early in my career at a company known as Nuvera, and that product is a multibillion-dollar treatment for ADHD known as Vyvanse. KP415 is kind of the other side of that coin. Vyvanse is an amphetamine-based treatment, similar to Adderall and Adderall XR. KP415 is actually a Ritalin-based or methylphenidate-based treatment. People pretty much split how they take these, like 40/60 or 60/40, depending on age and whatever works, but they both work for most patients. What we wanted to do was bring some of the patient benefits that we had heard so much about with Vyvanse to those folks that use the methylphenidate or Ritalin class of drugs more often. What does that mean for the user? Our clinical data shows that it starts at about a half an hour after it's administered, and it lasts for 13 hours. Say Johnny or Sally wake up at seven o'clock. By 7:30, well before they leave the house for the day, or in today's world before they go to a quiet place in the house for the day, you know the drug starts to work. They start to feel the effect and are able to focus. It’d be great if they remember their backpack and their shoes. By eight o'clock, at the end of the day, through activities and homework and dinner, it's still working. You still have that effect, but it starts to wear off so they can get to bed, and that truly is the benefit that folks haven't seen with these products.
Do you expect to grow your staff this year? I think that's more than likely going to happen. I think we have so much going on in different aspects, whether it's drug development, working with our established partners that are commercializing our products with us, whatever it is. You need resources to do so, and we focused our attention on getting the business to this point. Now we have to actually go back in and build in the necessary infrastructure. There's so much going on I expect that's going to be a natural effect. It’s nothing that today I can tell you definitively how many people that looks like.
Since 2018, KemPharm has eliminated $93.1 million in debt and regained its listing on the Nasdaq. What does that enable the company to do that it couldn’t before? We have an attractive pipeline of products. We have a unique technology, and all of those have been kind of put on the sideline a little bit. Now we're bringing them back up. Everything behind the business is fixed. Many pharma companies don't survive the amount of debt that we had without a revenue source. It was truly remarkable.
Two of KemPharm’s current drug candidates would treat ADHD and stimulant use disorder. Why does the firm focus in these areas? Prodrugs for me were always an attractive area to be in because it’s fairly straightforward scientifically, and you can add a lot of benefit… ADHD has been my focus my entire career. My children have it. I have it. I understand what it's like to live with it, and to be a parent in a home around it.
|
|
|
Post by JHam on Feb 6, 2021 4:36:12 GMT
|
|
|
Post by JHam on Feb 6, 2021 6:34:15 GMT
Finally got around to listening to the Investor Presentation day from Dec 2nd 2020. It's long but some very good stuff in it. The data is pretty impressive, and the team from Corium is the best there is when it comes to ADHD. Also, check out the list of drugs that the CEO of Coruim, Perry Sternberg (who is leading the commercialization effort) has brought to market: edge.media-server.com/mmc/p/wpaovm9r
|
|
|
Post by magnus123 on Feb 6, 2021 9:55:26 GMT
Next week should be on fire.
|
|
|
Post by JHam on Feb 8, 2021 11:21:26 GMT
Next week should be on fire. $8.49 (+14%) pre-market.
|
|
|
Post by magnus123 on Feb 8, 2021 14:34:59 GMT
Next week should be on fire. $8.49 (+14%) pre-market. And regular trading also strong! My prediction is that we will see $10+ this week.
|
|
|
Post by JHam on Feb 8, 2021 14:38:08 GMT
And regular trading also strong! My prediction is that we will see $10+ this week. This week? How about this hour?? Lol
|
|
|
Post by magnus123 on Feb 8, 2021 14:44:34 GMT
And regular trading also strong! My prediction is that we will see $10+ this week. This week? How about this hour?? Lol Wow. The crowd is coming in.
|
|
|
Post by JHam on Feb 8, 2021 14:51:08 GMT
This week? How about this hour?? Lol Wow. The crowd is coming in. This is fun to watch. I’m fully loaded at $6.19. Anxious to see how this plays out the next few weeks.
|
|
|
Post by selluwud on Feb 8, 2021 20:41:32 GMT
Wow. The crowd is coming in. This is fun to watch. I’m fully loaded at $6.19. Anxious to see how this plays out the next few weeks. Great pick here J. So far so good, biggest daily gainer % in my portfolio today. I also picked up some TRXC which ain't doing bad?
|
|
|
Post by JHam on Feb 9, 2021 1:41:05 GMT
This is fun to watch. I’m fully loaded at $6.19. Anxious to see how this plays out the next few weeks. Great pick here J. So far so good, biggest daily gainer % in my portfolio today. I also picked up some TRXC which ain't doing bad? TXRC is cruising. I didn’t have enough ammo left (since I had my eyes set on EQ) otherwise I probably would have joined you.
|
|
|
Post by JHam on Feb 9, 2021 4:59:47 GMT
This is fun to watch. I’m fully loaded at $6.19. Anxious to see how this plays out the next few weeks. Great pick here J. So far so good, biggest daily gainer % in my portfolio today. I also picked up some TRXC which ain't doing bad? Up 51% in two days with this one. No complaining here.
|
|
|
Post by JHam on Feb 9, 2021 15:16:09 GMT
Not surprised to see this in the red today. Yesterday was definitely a result of the Reddit pump. Traders are gonna do their thing and then I expect this to slowly continue to creep up heading into March.
|
|
|
Post by magnus123 on Feb 9, 2021 16:32:52 GMT
Not surprised to see this in the red today. Yesterday was definitely a result of the Reddit pump. Traders are gonna do their thing and then I expect this to slowly continue to creep up heading into March. Not unlikely that we will end the day positive. I see some similarities to the INMB run up, where we also had minor setbacks.
|
|
|
Post by magnus123 on Feb 9, 2021 22:51:18 GMT
KMPH paid down the last outstanding portion of it's debt with Deerfield.
|
|